2021
DOI: 10.1016/j.pcad.2021.03.008
|View full text |Cite
|
Sign up to set email alerts
|

Mitral valve diseases: Pathophysiology and interventions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(11 citation statements)
references
References 64 publications
0
11
0
Order By: Relevance
“…The main pathophysiological variation of mitral stenosis is that the stenotic mitral valve prevents the left atrium from emptying properly. Finally, pulmonary hypertension and right heart failure have occurred in severe cases [ 7 ]. The occurrence of valve disease, pulmonary hypertension, and coronary artery diseases dramatically enhances the risk of anaesthesia.…”
Section: Discussionmentioning
confidence: 99%
“…The main pathophysiological variation of mitral stenosis is that the stenotic mitral valve prevents the left atrium from emptying properly. Finally, pulmonary hypertension and right heart failure have occurred in severe cases [ 7 ]. The occurrence of valve disease, pulmonary hypertension, and coronary artery diseases dramatically enhances the risk of anaesthesia.…”
Section: Discussionmentioning
confidence: 99%
“…Minimally invasive cardiac surgery has become a new trend in modern medicine because of its reduced trauma, less bleeding and shorter post-operative recovery time [ 1 – 3 ], and there has been a significant increase in the number of studies related to minimally invasive mitral valve surgery [ 4 7 ]. Since minimally invasive mitral valve surgery was first described by Cohn and Cosgrove in the mid-1990s, a variety of minimally invasive procedures, including the parasternal, hemi-sternotomy, mini-thoracotomy, totally robotic approach, and totally endoscopic approach, have been proposed [ 8 ].…”
Section: Introductionmentioning
confidence: 99%
“…Transcatheter edge-to-edge repair (TEER) of the mitral valve (MV) caused a revolution in MR treatment when the MitraClip system (Abbott) was approved in Europe in 2008 for both indications, i.e., SMR and FMR, whereas it was approved in 2013 in the United States and only for SMR [ 3 ]. The treatment was primarily intended for FMR patients with very high operative risk, but it was soon adopted as an efficient therapeutic option in SMR patients with unacceptable operative risk [ 4 , 5 ]. More than one decade later, a new system for MV TEER, the PASCAL device (Edwards), was approved in Europe, but still not in the US.…”
Section: Introductionmentioning
confidence: 99%
“…Over more than one decade, our knowledge about MV repair has significantly increased; however, most published studies have been focused on the outcomes of MR patients after this procedure [ 4 , 5 ]. The demographic and clinical characteristics of SMR and FMR patients who underwent this procedure have been significantly less investigated.…”
Section: Introductionmentioning
confidence: 99%